We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
Date | Subject | Author | Discuss |
---|---|---|---|
08/2/2018 07:36 | Good rns this morning, should stop Gileard in their tracks, if they have infringed. | montyhedge | |
07/2/2018 23:00 | Competition in HIV was flagged in the call. It will be interesting to see how sales of Tivicay, Triumeq and the new Jaluca fare over the next 12-18 months as a result. | polaris | |
07/2/2018 22:10 | Even bears had to admit figures were as Emma said, outstanding. Free cash flow up 11% | montyhedge | |
07/2/2018 21:57 | Initially perhaps but I think GSK's two drug regimen is underestimated and as GSK says, theirs is the best treatment with the science to back it up. | romeike | |
07/2/2018 21:51 | Emma is very good. P.e 11.3, yield 6.3% not bad. | montyhedge | |
07/2/2018 20:49 | GSK's presentations worth a look. Great presentation, Emma an impressive communicator. hxxps://youtu.be/e79 | romeike | |
07/2/2018 20:32 | Pfizer's $20 Billion Pill Is Too Bitter for Glaxo The British drugmaker would be better off losing to Reckitt in the auction for its U.S. counterpart's consumer health business. | philanderer | |
07/2/2018 20:18 | FT: ......While refusing to comment on the auction for Pfizer’s unit, valued at roughly $14bn, Ms Walmsley said: “You would expect us to take a serious look at any leading and very appealing assets in the sector because we are a world leader in consumer healthcare and have a very good track record of integrating businesses successfully.” However, she played down the importance of a possible acquisition to GSK’s growth prospects, saying: “This is not a ‘need to do’. We are very happy with our consumer business .&th | philanderer | |
07/2/2018 20:15 | 'GSK chief urges government to secure Brexit transition deal by April' Emma Walmsley says a close relationship with the EU after leaving is vital for the future of the UK’s pharma industry | philanderer | |
07/2/2018 16:42 | Is this money or shares? | abdullla | |
07/2/2018 16:41 | Outstanding results should 1485p not 1285p. Analysts must up their targets now. | montyhedge | |
07/2/2018 16:37 | Bought 2.25K shares pretty much at the bottom - well pleased. 23p divi soon come too! | woodhawk | |
07/2/2018 16:23 | What a difference a day makes | badtime | |
07/2/2018 16:20 | For anyone interested GlaxoSmithKline 2017 Q4 - Results - Earnings Call Slides | fangorn2 | |
07/2/2018 16:04 | Profits banked :) | wipo1 | |
07/2/2018 15:21 | I do hope I'm not being accused of being a nigel... | imastu pidgitaswell | |
07/2/2018 14:52 | Ex Dividend is 22nd Feb, 23p paid. I don't think it will fall much say 5p. | montyhedge | |
07/2/2018 14:52 | One against the head for the English........ | penycae | |
07/2/2018 14:37 | I just bought some of these at 1252. Then I saw this, further up the thread: Penycae 7 Feb '18 - 13:07 - 16540 of 16556 0 0 0 Regrets, I've had a few... :-) | imastu pidgitaswell | |
07/2/2018 14:19 | God help us if the update had been bad! | tim 3 | |
07/2/2018 13:59 | 'GSK provides reassuring prognosis for annual dividend' | philanderer | |
07/2/2018 13:54 | Not much sadder than punters cashing in for a 1% profit. Slow clap. Gain on strong results from Tullow similarly sold into. Rigged market to feed the suited pigs. | romeike |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions